不同治疗方式对术后伴中危因素Ⅰ-ⅡA期宫颈癌预后影响

doi:10.3760/cma.j.issn.1004-4221.2019.05.008

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的比较不同治疗方式对伴中危因素的Ⅰ-ⅡA期宫颈癌患者的生存差异,探讨早期宫颈癌术后伴中危因素患者的最佳治疗模式。方法回顾分析2007-2016年间收治的包含中危因素的323例宫颈癌术后患者,比较观察(NT)、单纯化疗(CT)、放疗(RT)及同步放化疗(CCRT)方式对生存的影响。Kaplan-Meier法生存分析,Logrank检验差异,Cox模型行预后因素分析。结果全组的5年PFS、OS为79.0%、84.8%。单因素及多因素分析肿瘤大小>4 cm、治疗方式是影响PFS的因素(P=0.017、0.002),危险因素个数、治疗方式是影响OS的因素(P=0.042、0.000)。全组中RT及CCRT均可改善患者预后(P=0.007、0.000)。亚组分析中任意1个中危因素(低危组),CT能够延长5年PFS (P=0.026),在改善5年OS上相近(P=0.692);与NT及CT相比,RT及CCRT均能改善患者预后(P=0.006、0.000),但RT与CCRT相近(P=0.820、0.426)。≥2个中危因素(高危组)中,与CT相比,CCRT能提高患者的5年PFS (P=0.006),但不能延长患者5年OS (P=0.107);RT与CCRT比较,CCRT均可改善患者的预后(P=0.028、0.039)。结论仅有1个中危因素时,RT也能改善预后;伴有≥2个中危因素时,CCRT更能改善患者的预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吉维
	冉立
	常建英
	李凤虎
	李杰慧
	刘光荣
	余淼

关键词 ：宫颈肿瘤/放射疗法, 宫颈肿瘤/化学疗法, 宫颈肿瘤/同步放化疗法, 预后

Abstract：Objective To compare the effect of different therapeutic Methods upon the survival of stage Ⅰ-ⅡA cervical cancer patients with intermediate risk factors and explore the optimal treatment for patients with early-stage cervical cancer undergoing radical hysterectomy and pelvic lymphadenectomy.Methods Clinical data of 323 patients with the following intermediate risk factors of lymphovascular space invasion, depth of stromal invasion or tumor size>4 cm were retrospectively analyzed. The impact of observing (NT),chemotherapy (CT),radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) on survival was statistically compared. The Kaplan-Meier method was used to survival analysis,and log-rank test difference,Cox model was used to prognostic factor analysis.Results The 5-year progression-free survival (PFS) and overall survival (OS) of all patients were 79.0% and 84.8%. Univariate and multivariate analyses demonstrated that TS> 4 cm and therapeutic method were the independent prognostic factors of PFS. The number of risk factors and therapeutic method were the independent prognostic factors of OS. In the whole group, both RT and CCRT could improve the prognosis of patients with no statistical significance (P>0.05). In the subgroup analysis, for patients with a single intermediate risk factor (low risk group), CT could significantly prolong the PFS (P=0.026) rather the 5-year OS (P=0.692). Compared with NT and CT, RT and CCRT could improve the PFS and OS, whereas no statistical significance was noted between the RT and CCRT (both P>0.05). For those with ≥2 risk factors (high risk group), CCRT could significantly prolong the PFS compared with CT (84.9% vs. 70%;P=0.006), but did not improve the OS (P=0.107). Compared with RT, CCRT could significantly improve the PFS and OS (both P<0.05).Conclusions For patients with only one risk factor, RT can enhance the clinical prognosis. CCRT can improve the clinical prognosis of stage Ⅰ-ⅡA cervical cancer patients with ≥2 risk factors.

Key words： Cervical neoplasms/radiotherapy Cervical neoplasms/chemotherapy Cervical neoplasms/ concurrent chemoradiotherapy Prognosis

收稿日期: 2018-12-10

基金资助:磁性纳米微粒MR成像对子宫颈癌淋巴结转移诊断和调强放疗靶区勾画的指引(黔科合外G字[2012]7048号)

通讯作者: 冉立,Email:ranli171@hotmail.com

引用本文:

吉维,冉立,常建英等. 不同治疗方式对术后伴中危因素Ⅰ-ⅡA期宫颈癌预后影响[J]. 中华放射肿瘤学杂志, 2019, 28(5): 358-363.

Ji Wei,Ran Li,Chang Jianying et al. Effect of different therapeutic methods on survival of stage Ⅰ-ⅡA cervical cancer patients complicated with postoperative intermediate risk factors[J]. Chinese Journal of Radiation Oncology, 2019, 28(5): 358-363.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2019.05.008 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2019/V28/I5/358

[1]Samlal RA,van der Velden J,Schilthuis MS,et al. Identification of high-risk groups among node-positive patients with stage ⅠB and ⅡA cervical carcinoma[J].Gynecol Oncol,1997,64(3):463-467.DOI:10.1006/gyno.1996.4576.
[2]Van de Putte G,Lie AK,Vach W,et al. Risk grouping in stage ⅠB squamous cell cervical carcinoma[J].Gynecol Oncol,2005,99(1):106-112.DOI:10.1016/j.ygyno.2005.05.026.
[3]Sedlis A,Bundy BN,Rotman MZ,et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage ⅠB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy:a Gynecologic Oncology Group Study[J].Gynecol Oncol,1999,73(2):177-183.DOI:10.1006/gyno.1999.5387.
[4]Ryu SY,Park SI,Nam BH,et al. Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors?[J].Int J Radiat Oncol Biol Phys,2011,79(3):794-799.DOI:10.1016/j.ijrobp.2009.11.019.
[5]Ryu SY,Kim MH,Nam BH,et al. Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy:a Korean Gynecologic Oncology Group study[J].Br J Cancer,2014,110(2):278-285.DOI:10.1038/bjc.2013.716.
[6]Davila FR,Rob VO,Buist MR,et al. Post-operative radiotherapy in patients with early stage cervical cancer[J].Gynecol Oncol,2014,134(1):52-59.DOI:10.1016/j.ygyno.2014.04.045.
[7]Scandurra G,Scibilia G,Banna GL,et al. Efficacy and tolerability of paclitaxel,ifosfamide,and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma[J].J Gynecol Oncol,2015,26(1):118-124.DOI:10.3802/jgo.2015.26.2.118.
[8]Delgado G,Bundy B,Zaino R,et al. Prospective surgical-pathological study of disease-free interval in patients with stage ⅠB squamous cell carcinoma of the cervix:a gynecologic oncology group study[J].Gynecol Oncol,1990,38(3):352-357.DOI:10.1016/0090-8258(90)90072-S.
[9]Sun HY,Tang Q,Chen JH,et al. Cisplatin concurrent chemoradiotherapy vs. adjuvant radiation in stage ⅠB/ⅡA cervical cancer with intermediate risk factors,treated with radical surgery:a retrospective study[J].Oncol Targ Ther,2018, 6(11):1149-1155.DOI:10.2147/OTT.S158214.
[10]Stehman FB,Bundy BN,DiSaia PJ,et al. Carcinoma of the cervix treated with radiation therapy. I.A multi-variate analysis of prognostic variables in the gynecologic oncology group[J].Cancer-am Cancer,1991,67(11):2776-2785.DOI:10.1002/cncr.2820710439.
[11]Yang K,Park W,Huh SJ,et al. Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer[J].Radiat Oncol J,2017,35(1):39-47.DOI:10.3857/roj.2016.01893.
[12]Hosaka M,Watari H,Takeda M,et al. Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy[J].J Obstet Gynaecol Res,2008,34(4):552-556.DOI:10.1111/j.1447-0756.2008.00739.x.
[13]Takeshima N,Umayahara K,Fujiwara K,et al. Treatment Results of adjuvant chemotherapy after radical hysterectomy for intermediate-and high-risk stage ⅠB-ⅡA cervical cancer[J].Gynecol Oncol,2006,103(2):618-622.DOI:10.1016/j.ygyno.2006.04.019.
[14]Stehman FB,Ali S,Keys HM,et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma:follow-up of a gynecologic oncology group trial[J].Am J Obstel Gynecol,2007,197(1):1-6.DOI:10.1016/j.ajog.2007.08.003.
[15]唐秋,屠晔强,陈建红.同步放化疗治疗早期宫颈癌术后中危患者的疗效分析[J].中华肿瘤杂志,2018,40(6):462-466.DOI:10.3760/cma.j.issn.0253-3766.2018.06.012.
Tang Q,Tu YQ,Chen JH.Therapeutic effect of synchronous radiotherapy and chemotherapy on patients with early cervical cancer after operation[J].Chin J Oncol,2018,40(6):462-466.DOI:10.3760/cma.j.issn.0253-3766.2018.06.012.
[16]Stehman FB,Ali S,Keys HM,et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma:follow-up of a Gynecologic Oncology Group trial[J].Am J Obstet Gynecol. 2007,197(5):503.e1-6.DOI:10.1016/j.ajog.2007.08.003.
[17]Nakamura K,Kitahara Y,Satoh T,et al. Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage ⅠB1 cervical cancer patients with intermediate risk factors (GOTIC study)[J].World J Surg Oncol,2016,14(1):173.DOI:10.1186/s12957-016-0931-4.